论文部分内容阅读
趋化因子受体7(CC chemokine receptor 7,CCR7),主要表达于树突状细胞、淋巴细胞和各种肿瘤细胞表面,在树突状细胞抗肿瘤免疫应答和促进肿瘤侵袭和淋巴转移过程中发挥着不容忽视的作用。一方面,CCR7使活化的成熟DC通过输入淋巴管进入淋巴结,引导负载抗原的(dendritic cell,DC)从肿瘤部位迁移至淋巴组织,在诱导DC的抗肿瘤免疫反应中起重要作用;另一方面,CCR7在多种肿瘤如乳腺癌、非小细胞肺癌、结肠癌、胃癌等中表达,而淋巴结中丰富的CCL21则能趋化CCR7阳性的肿瘤细胞向淋巴结转移,直接导致肿瘤的扩散。CCR7在免疫细胞和肿瘤细胞共同表达的这一特点决定了其很有可能成为DC疫苗免疫效果和DC功能评价,以及某些实体瘤淋巴结转移评价乃至治疗的新靶点。
CC chemokine receptor 7 (CCR7) is mainly expressed on the surface of dendritic cells, lymphocytes and various tumor cells. In the process of anti-tumor immune response of dendritic cells and promotion of tumor invasion and lymphatic metastasis Play a role that can not be ignored. On the one hand, CCR7 plays an important role in inducing the anti-tumor immune response of DC by allowing activated mature DCs to enter the lymph nodes through the input of lymphatic vessels and guide the migration of dendritic cells (DCs) from tumor sites to lymphoid tissues. On the other hand , CCR7 is expressed in many kinds of tumors such as breast cancer, non-small cell lung cancer, colon cancer and gastric cancer. CCL21 rich in lymph nodes can chemotactic the CCR7 positive tumor cells to lymph node metastasis, which directly leads to tumor spread. The fact that CCR7 is co-expressed in immune cells and tumor cells determines that it is likely to become a new target for the evaluation of DC vaccine immune function and DC function as well as for the evaluation and even treatment of some solid tumors with lymph node metastasis.